SBIR Phase I: Marker Gene Directed Substrates for Cell Regulation

SBIR 第一阶段：用于细胞调控的标记基因定向基质

• 批准号: 9561199
• 负责人: John Naleway
• 金额: $ 7.42万
• 依托单位: MARKER GENE TECHNOLOGIES, INC
• 依托单位国家: 美国
• 项目类别: Standard Grant
• 财政年份: 1996
• 资助国家: 美国
• 起止时间: 1996-02-01 至 1996-09-30
• 项目状态: 已结题
• 来源: https://www.nsf.gov/awardsearch/showAward?AWD_ID=9561199&HistoricalAwards=false
• 关键词: SBIR; Phase; Marker; Gene; Directed

9561199 Naleway This Small Business Innovation Research Phase I project aims to investigate the feasibility of developing new compounds capable of utilizing common marker gene expression in transformed cells to control the growth and character of cells in living tissue. If successful, the research will provide breakthroughs needed to advance the promising commercial uses of recombinant genes. Marker Gene Technologies will establish the feasibility of the technology by preparing new galactoside and Cephalosporin conjugates of common growth regulators, drugs and enzyme inhibitors, for administration to a variety of animal cells or bacteria that contain either the B-galactosidase (lac Z) or ampicillin resistance (B-lactamase, amp) genes as gene fusion markers. These new conjugates will provide innovative methods of detecting gene fusion's and utilizing these fusion systems in transformed cells to control selected biological properties of the cells. The new conjugates will be assayed in tissue culture and in vivo for their ability to cause specific and localized inhibition or improvement of cell growth in culture and to deliver these conjugates in a cell- or tissue-specific manner. This work will provide the foundation for the next phase of the project in which the conjugates will be tested in a variety of commercial applications. Marker Gene Technologies brings 12 years of experience in the area of marker gene research to this project. The company sells a variety of market gene-directed conjugates, molecular biology kits, and inhibitors to the worldwide scientific community. The success of this project opens up significant commercial possibilities in the fields of plant and crop production, medical intervention in genetic diseases, immunoadjuvant therapy for cancer treatment, and biotechnological production of new proteins and drugs in cell-culture systems. In addition, it contributes new information and techniques for basic cell-biology research.

小行星9561199 该小型企业创新研究第一阶段项目旨在研究开发能够利用转化细胞中常见标记基因表达的新化合物的可行性，以控制活组织中细胞的生长和特性。 如果成功的话，这项研究将为推进重组基因的有前景的商业用途提供突破。 Marker Gene Technologies将通过制备常见生长调节剂、药物和酶抑制剂的新半乳糖苷和头孢菌素缀合物来确定该技术的可行性，用于对含有作为基因融合标记的B-半乳糖苷酶（lac Z）或氨苄青霉素抗性（B-内酰胺酶，amp）基因的各种动物细胞或细菌进行给药。 这些新的缀合物将提供检测基因融合的创新方法，并在转化细胞中利用这些融合系统来控制细胞的选定生物学特性。 将在组织培养物和体内测定新缀合物引起培养物中细胞生长的特异性和局部抑制或改善的能力，以及以细胞或组织特异性方式递送这些缀合物的能力。这项工作将为项目的下一阶段提供基础，其中结合物将在各种商业应用中进行测试。 Marker Gene Technologies为该项目带来了12年的标记基因研究经验。 该公司向全球科学界销售各种市场基因导向缀合物、分子生物学试剂盒和抑制剂。 该项目的成功为植物和作物生产、遗传疾病的医疗干预、癌症治疗的免疫辅助疗法以及细胞培养系统中新蛋白质和药物的生物技术生产等领域开辟了重要的商业可能性。 此外，它还为基础细胞生物学研究提供了新的信息和技术。